Irbesartan Tablet
Product Images NDC 31722-160

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 31722-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Irbesartan150mg1000s (Irbesartan150mg1000s)

Label for Irbesartan Tablets, USP 150 mg by Camber Pharmaceuticals, Inc. The oral tablet package contains 1,000 tablets. The label includes dosage strength, storage instructions at 20° to 25°C with excursions permitted to 15° to 30°C, and a note to see the package insert for dosing. It features the NDC number 31722-161-10, barcode, and manufacturer information for Camber Pharmaceuticals, Inc. and ScleGen Pharmaceuticals, Inc.*

FDA Label Image

Irbesartan300mg500s (Irbesartan300mg500s)

Label for Irbesartan Tablets, USP 300 mg by Camber Pharmaceuticals, Inc., containing 500 tablets. The label displays storage instructions, dosage information, barcode, and manufacturer details including Camber Pharmaceuticals and ScieGen Pharmaceuticals. It cautions to keep medication out of children’s reach.*

FDA Label Image

Irbesartan75mg500s (Irbesartan75mg500s)

Label for Irbesartan Tablets, USP 75 mg from Camber Pharmaceuticals, Inc. The label states it contains 500 tablets, is for prescription use only, and provides storage instructions between 20° to 25°C with permitted excursions. It also includes manufacturing details for Camber Pharmaceuticals, Inc. in Piscataway, NJ, and SoleGen Pharmaceuticals, Inc. in Hauppauge, NY.*

FDA Label Image

Irbesartanfigure1and2 (Irbesartanfigure1and2)

Two scatter plots with curves depicting the relationship between Irbesartan dose in mg/kg and the reduction in blood pressure parameters. The first figure shows dose versus systolic blood pressure reduction from placebo-subtracted results, and the second figure shows dose versus trough systolic blood pressure reduction with irregular analysis. Both graphs illustrate dose-response trends for Irbesartan.*

FDA Label Image

Irbesartanfigure3 (Irbesartanfigure3)

A Kaplan-Meier estimate graph showing the cumulative event rate (%) for the primary endpoint (doubling of serum creatinine, end-stage renal disease, or all-cause mortality) over months of follow-up (0 to 60). The graph compares three groups: Irbesartan, Amlodipine, and Placebo, with Irbesartan and Placebo showing the highest event rates and Amlodipine the lowest. A table inset provides hazard ratios (HR) and p-values (P) for Irbesartan versus Placebo and Amlodipine comparisons.*

FDA Label Image

Irbesartanstructure (Irbesartanstructure)

Chemical structure of irbesartan, a pharmaceutical active ingredient used in prescription tablets. The diagram shows the molecular connectivity and arrangement of atoms specific to irbesartan.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.